Media coverage about Immuron Limited – American Depositary Shares (NASDAQ:IMRN) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Immuron Limited – American Depositary Shares earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.8534054544205 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Immuron Limited – American Depositary Shares (NASDAQ IMRN) opened at $5.22 on Thursday. Immuron Limited – American Depositary Shares has a twelve month low of $4.47 and a twelve month high of $16.34.
Separately, HC Wainwright initiated coverage on Immuron Limited – American Depositary Shares in a report on Wednesday, October 18th. They set a “buy” rating and a $15.00 target price on the stock.
About Immuron Limited – American Depositary Shares
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.